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1 
INTRODUCTION 
 
 
                        The urogenital microflora of a healthy woman comprises 
approximately 50 species of organisms, 1 that differs in composition according to 
the reproductive stages and exposure to several factors, including antibiotics2 
and spermicides.3 Urogenital infections include those that affect the urethra, 
urinary bladder, vagina and cervix and constitute a worldwide problem that 
affects more than 300 million women/year.  
                       Common urogenital infections include bacterial vaginosis (BV), 
vulvovaginal candidiasis (VVC/yeast vaginitis), and urinary tract infections (UTI). 
At the time of infection in the bladder and vagina, the urogenital flora is often 
dominated by the infecting pathogens, in contrast with healthy phases when 
indigenous organisms dominate. Although antimicrobial therapy is generally 
effective at eradicating these infections, there is still a high incidence of 
recurrence. The patient's quality of life is affected and there is a cycle of repeated 
antimicrobial agents whose effectiveness is diminishing due to increasing 
development of microbial resistance.    
                          There is now growing evidence that certain species and strains 
present in the healthy urogenital tract protect the host against infection by 
pathogenic microorganisms. The dominant presence of lactobacilli in the 
urogenital microflora of healthy women and the obliteration of lactobacilli in 
patients who develop UTI, 4,5 BV, and many other genital infections has led to a 
focus on these bacteria. 
2 
                          Lactobacilli are gram-positive rods, primarily facultative or strict 
anaerobes that generally have a fastidious growth requirement. They prefer an 
acidic environment and help create one by producing lactic and other acids. In 
general, lactobacilli have not been associated with disease and for more than 
100 years have been regarded as nonpathogenic members of the intestinal and 
urogenital floras. Premenopausal women have a flora of mostly lactobacilli, and 
certain properties of these strains, including adhesive ability, production of acids, 
bacteriocins, hydrogen peroxide, and biosurfactants appear important in 
conferring protection to the host. 
                            The term probiotic was derived from the Greek, meaning “for 
life.” An expert panel commissioned by the Food and Agriculture Organization of 
the United Nations (FAO) and the World Health Organization (WHO) defined 
probiotics as “Live microorganisms which when administered in adequate 
amounts confer a health benefit on the host.” 6 Ingestion of Probiotics beneficially 
affects the host by – 
1) Replenishing the depleted gut microflora, and 
2) Improving the   properties of   the indigenous microflora. 
 
 
 
 
                               
3       
                      Two Lactobacilli strains - Lactobacillus rhamnosus GR-1 and 
Lactobacillus reuteri RC-14 are clinically documented and they possess 
antipathogenic properties and colonize in the intestine7 and in the urogenital 
tract,8  conferring health benefits to women.  
                       We conducted this study to evaluate the efficacy of probiotic   
Lactobacilli strains - Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-
14 as integral therapy with conventional treatment of female urogenital infections 
namely  - 
 Bacterial vaginosis (BV), 
 Vulvovaginal candidiasis (VVC/yeast vaginitis) and 
 Urinary tract infections (UTI). 
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REVIEW OF LITERATURE 
                     In great number and diversity, microbes inhabit the intestinal tract, 
skin and urogenital tract, oral and nasal cavities and, in short, any part of the 
human body that is exposed to the outside world and in which conditions are 
favorable for bacterial survival. Hundreds of species have been identified as 
human commensals. Bacterial concentrations reach 1013 cells on the human 
body.9                             
                              Studies from germ-free animals have proven that animals do not 
require microbial colonization for survival, but germ-free animals, compared with 
their conventional counterparts, demonstrate many physiologic and biochemical 
differences and are more susceptible to infection.10 This is attributed to a poorly 
primed immune system and perhaps the absence of what has been termed 
"competitive colonization" .11Competitive colonization is a term describing the 
interference of virulence of invading pathogens by commensal microbes. The 
differences between conventional and germ-free animals have provided a basis 
for the belief that microbial colonization has important health implications for 
humans. 
HISTORICAL PERSPECTIVE 
                     The age-old quote, “Let food be thy medicine and medicine be thy 
food” is certainly the tenet of today. There is a long history of health claims 
concerning living microorganisms in food, particularly lactic acid bacteria. In 76 
BC, a Roman historian recommended the administration of fermented milk 
5 
 products for treating gastroenteritis.12 Administration of bifidobacteria was found 
to be effective in infants suffering from diarrhoea.13A Russian Immunologist 
linked the bacterium Lactobacillus bulgaricus in yoghurt to the longevity of 
Bulgarians who ate large quantities of yoghurt.14  
 
PROBIOTICS 
                        In 1965, the term ‘probiotic’ was used to describe growth 
promoting factors produced by microorganisms.15 The term probiotic was derived 
from the Greek word  ”pro bios” meaning “for life.” In 2002, an expert panel 
commissioned by the Food and Agriculture Organization of the United Nations 
(FAO) and the World Health Organization (WHO) defined probiotics as “Live 
microorganisms which when administered in adequate amounts confer a health 
benefit on the host.” 6 
 
MICROORGANISMS USED AS PROBIOTICS 
                                        The most common probiotic microorganisms that have 
been found to be clinically useful include members of the genera Lactobacillus 
and Bifidobacterium and the species of most interest for efficacy testing include 
Lactobacillus acidophilus, L. johnsonii, L. casei, L. gasseri, L. plantarum, L. 
rhamnosus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium 
bifidum and Bifidobacterium infantis.16 Table 1 lists down the microorganisms 
used as probiotics.17 
  
TABLE – 1 
 
 
Microorganisms Used As Probiotics 17 
A. BACTERIA 
Lactobacillus 
species 
Bifidobacterium 
species 
Other lactic acid 
bacteria 
 
Non-lactic acid 
bacteria 
 
L. acidophilus 
 
L. amylovorus 
 
L. casei 
 
L. crispatus 
 
L.delbrueckii  
  bulgaricus  
 
L. gallinarum 
 
L. gasseri  
 
L. johnsonii  
 
L. paracasei 
 
 L. plantarum  
 
L. reuteri  
 
L. rhamnosus 
 
 
B. adolescentis 
 
B. animalis 
 
B. bifidum 
 
B. breve 
 
B. infantis 
 
B. lactis 
 
B. longum 
 
Enterococcus faecalis 
 
Enterococcus faecium 
 
Lactococcus lactis 
 
Leuconstoc             
mesenteroides 
 
Pediococcus acidilactici 
 
Sporolactobacillus 
inulinus 
 
Streptococcus 
thermophilus 
 
Streptococcus lactis 
 
Streptococcus 
intermedius 
 
 
 
Bacillus cereus        
var. toyoi 
 
Escherichia coli 
strain nissle 
 
Propionibacterium 
freudenreichii, 
 
B. YEAST AND MOULDS 
Aspergillus cerevisiae, Aspergillus niger, Aspergillus oryzue, Candida intolopesii, 
Sacharomyces boulardii. 
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THE IDEAL PROBIOTIC SUPPLEMENT 
                          A summary of conventional criteria that are used for the 
selection of microbial strains to be used as probiotics includes the following 
properties.18 
1) Strain origin - Those isolated from the same species as the intended use 
have an enhanced chance of survival.  
2) Strain count - The supplement should have adequate number of colony 
forming units (CFUs) to confer a health benefit.19To achieve health 
benefits, probiotic bacteria must be viable and available at a high 
concentration, typically 106–107 CFUs/gm of product.20 
3) Strain taxonomy - The probiotic strain should be identified by an accurate 
taxonomy. 18 
4) Inhabitation - Should be a normal inhabitant of the human species. 
5) Biosafety - Probiotics are generally recognized as safe. They should be 
non-toxic and non-pathogenic.  
6) Survivability - Both in the formulation and after digestion, strains that 
have improved resistance to acid, bile and adherence to the gut epithelium 
have better survival characteristics. 21 
7) Production characteristics and processing - Amenable to production 
processing: adequate growth in bulk culture, recovery, concentration, 
freezing, dehydration, storage and distribution. 
 
7 
8) Effect on the consumer –Should be able to exert one or more clinically 
documented health benefits. Adverse side effects such as bloating and 
effects on gut transit should not occur. 
9) Genetic stability – Should be genetically stable.  
10) Viability – Should be viable at high populations during storage and use. 21 
11) Produce antimicrobial substances – Should be able to produce anti-
microbial substances including bacteriocins, H2O2 and organic acids.  
Lactobacillus rhamnosus strain GG meets most of the above criteria. 21 
 
PROBIOTICS AS THERAPEUTIC TOOLS 
A. Infectious Diarrhoea - Resistance To Enteric Pathogens 
 
                          Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12 
are used for the prevention 22 and treatment 23 of acute diarrhea caused by 
rotaviruses and other enteropathogens. 24 The postulated mechanisms are- 
1) Secretory immune effect. 22 
2) Alteration of intestinal conditions to be less favorable for pathogenicity. 
(pH, short chain fatty acids, bacteriocins) 
3) Adherence to intestinal mucosa, interfering with pathogen adherence.25 
4) Upregulation of intestinal mucin production, interfering with pathogen 
attachment to intestinal epithelial cells. 24 
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B. Anti-Microbial Agent Associated Diarrhoea  
 
                     A major problem associated with antibiotic treatment is the 
appearance of diarrhoea, often caused by Clostridium difficile. Probiotics have 
proved useful as a prophylactic regimen, and are used to alleviate the signs and 
symptoms of antibiotic induced diarrhea.26 
C. Helicobacter Pylori Infection  
 
                    In vitro and animal data indicate that lactic acid bacteria inhibit the 
growth of the H.pylori and decrease the urease enzyme activity necessary for the 
pathogen to remain in the acidic environment of the stomach.27 
D. Lactose intolerance 
 
                    Probiotic bacterial lactase causes hydrolysis of lactose and is used 
to alleviate the signs and symptoms of lactose intolerance. 
E. Immune System Modulation 
 
                     B. lactis HN019 and L. rhamnosus HN001 produce measurable 
enhancement of immune responses by activating macrophages and by 
increasing the level and activity of cytokines, natural killer cells and secretory 
immunoglobulin A. 28  
F. Hepatic Encephalopathy 
 
                     Probiotics produce inhibition of urease-producing gut flora. 
G. Anti Cancer Effect 
 
                    There is some evidence that cancer recurrences at urinary bladder 
can be reduced by intestinal instillation of probiotics like L. casei shirota29 which  
9 
act by-   mutagen binding, carcinogen (nitrosamine) deactivation and inhibition of 
carcinogen-producing enzymes of colonic microbes. 29 
H. Allergy 
                     Probiotic microorganisms like L. rhamnosus GG modulate the 
immune response and prevent the onset of allergic diseases.30 
I. Inflammatory Diseases And Bowel Syndromes 
                       Probiotic strains have a potential role in the therapy and 
prophylaxis of irritable bowel syndrome and inflammatory bowel diseases, such 
as pouchitis and Crohn’s disease. 31 
J. Effects on blood lipids 
 
                        The proposed hypocholesterolemic action of probiotic strains 
include assimilation of cholesterol within bacterial cell, antioxidative effect and 
increased excretion of bile salts due to deconjugation by bile salt hydrolase.32 
K. Antihypertensive Effect 
 
                         Bacterial peptidase action yields tripeptides, which function as 
angiotensin-converting enzyme inhibitors mediating a mild antihypertensive 
effect.33 
DYNAMICS OF UROGENITAL MICROFLORA 
               The microbiological flora of the lower female genital tract is a dynamic, 
complex example of microbial colonization and what constitutes a pathogen is 
dependent not only on the type of offending microorganism and its intrinsic 
virulence but, also, on the species complexity of the flora. 
               10 
               Lactobacilli are both the predominant bacteria in the vaginal tract and 
the regulator of normal vaginal flora.34 Lactobacilli by producing lactic acid, 
maintain the normal vaginal pH of 3.8 to 4.5, and inhibit the adherence of bacteria 
to vaginal epithelial cells. Estrogen improves lactobacilli colonization by 
enhancing vaginal epithelial-cell production of glycogen, which breaks down into 
glucose and acts as a substrate for the bacteria. 
              Quantitative studies have reported that vaginal washings contain 
approximately 107 lactobacilli per gram of secretion. The most common 
Lactobacillus species include L. acidophilus and L. fermentum; less common are 
L. plantarum, L. brevis, L. jensenii, L. casei, L. delbrueckii, and L. salivarius. More 
than one species may be present in an individual.34 Although lactobacilli are the 
dominant bacteria, other bacteria are also present in the vagina, including 
streptococcal species, gram-negative bacteria, Gardnerella vaginalis, and 
anaerobes. Candida albicans is found in normal flora as a commensal agent in 10 
to 25% of asymptomatic women.35 
             Scientific studies showed a significant correlation between the absence 
of hydrogen peroxide producing lactobacilli and vaginal colonization by G. 
vaginalis, Bacteroides species, Peptostreptococcus species, and Mycoplasma 
hominis.36 Inhibitory proteins have been isolated from strains of Lactobacillus 
acidophilus.37 
                  The uropathogens and non-pathogenic lactobacilli originate from the host 
microbial flora and most commonly from the faecal flora 38 as depicted in figure 1. 
  
Figure 1 Bacteria emerging from the colon to colonise the vagina. 
 
 
 
Figure 2   Byproducts of lactobacillus metabolism 
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                  Figure 2 depicts the various byproducts of lactobacillus metabolism 
like biosurfactants, acids, bacteriocins, hydrogen peroxide and coaggregation 
molecules that have an antagonistic effect against urinary and vaginal 
pathogens. The biosurfactants inhibit adhesion; the acids, bacteriocins, and 
hydrogen peroxide inhibit growth; and the coaggregation molecules block the 
spread of the pathogens.38 
                                 L. rhamnosus GR-1 and L. reuteri RC-14 are extensively 
characterized urogenital isolates which possess a number of properties 
considered important for urogenital probiotics; both strains adhere to uroepithelial 
cells and inhibit the growth and adhesion of uropathogens, while GR-1 is 
resistant to the spermicide nonoxynol 9 and RC-14 produces hydrogen 
peroxide..39 Furthermore, studies with humans have shown that these strains are 
efficacious in the prevention and treatment of urogenital infections in women.40, 41 
UROGENITAL INFECTIONS 
                          Urogenital infections include those that affect the urethra, urinary 
bladder, vagina and cervix and constitute a worldwide problem that affects more 
than 300 million women/year. Common urogenital infections include bacterial 
vaginosis (BV), vulvovaginal candidiasis (VVC/yeast vaginitis), and urinary tract 
infections (UTI).  
BACTERIAL VAGINOSIS 
                       Bacterial vaginosis previously known as nonspecific vaginitis or 
Gardnerella vaginitis is the most common cause of acute vaginitis and accounts  
12 
for 15 to 50% of the cases in symptomatic women.42 It is characterized by a 
disequilibrium in vaginal microflora in which the normally predominant hydrogen 
peroxide–producing strains of lactobacilli are overgrown by facultative and 
anaerobic vaginal microorganisms.43 BV is associated with significant 
complications like cervicitis44, endometritis, 45 HIV infection46 and preterm 
labour.47 
                    The diagnosis of BV is made by the use of clinical criteria or Gram 
stain. At least three of the following four elements must be present to fulfill the 
clinical criteria of Amsel et al. for bacterial vaginosis48: 
• thin, homogeneous, milky vaginal discharge; 
• vaginal-fluid pH greater than 4.5;  
• a positive whiff test (i.e., production of a fishy odor when 10 percent 
potassium hydroxide is added to a slide containing vaginal-fluid); and 
• clue cells (>20 percent of epithelial cells with adherent bacteria) on 
microscopic examination of vaginal fluid.  
An alternative diagnostic approach is Gram's staining of vaginal fluid to 
distinguish normal vaginal flora (i.e., gram-positive rods and lactobacilli) from 
bacterial vaginosis flora according to the Nugent score.49 The specificity and 
sensitivity of the Gram stain for diagnosis of BV are 83% and 89% respectively.50 
 
 
 
 Figure 3 Normal vaginal smear: Lactobacillus dominant. 
 
 
Figure 4 Vaginal smear in bacterial vaginosis 
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                      Figure 3 shows the normal vaginal Gram stained smear with 
dominant lactobacillus (long Gram positive rods). Figure 4 shows the vaginal 
smear in bacterial vaginosis in which there is few or absent lactobacilli (long 
Gram positive rods) and greatly increased number of small Gram negative or 
Gram variable rods or both. 
NUGENT'S DIAGNOSTIC CRITERIA FOR BACTERIAL VAGINOSIS49  
Scoring system (zero to 7+)* is a weighted combination of the following bacterial 
morphotypes: 
A. Lactobacillus acidophilus (large gram-positive rods) 
B. Gardnerella vaginalis and Bacteroides species (small gram-variable or 
gram-negative rods) 
C. Mobiluncus species (curved gram-variable rods)  
The total score is the sum of the weighted quantity of the three bacterial 
morphotypes.  
Scoring for each of the above bacterial morphotypes: 
Zero = No morphotypes per oil-immersion field 
1+ = Less than one morphotype per oil-immersion field  
2+ = One to four morphotypes per oil-immersion field 
3+ = Five to 30 morphotypes per oil-immersion field 
4+ = More than 30 morphotypes per oil-immersion field 
For the combined score (A + B + C), zero to 3 represents normal flora, 4 to 6 
represents indeterminate, and 7 or higher is diagnostic of bacterial vaginosis 
14 
                      Currently, metronidazole is the agent of choice for the treatment of 
bacterial vaginosis. This therapy is moderately effective against G vaginalis and 
Mobiluncus spp and is inactive against Mycoplasma hominis but its metabolites 
are highly active against anaerobes. There are two recommended dosage 
regimens for oral metronidazole: 500 mg twice daily for seven days or 2 gm given 
in a single oral dose.51 Unfortunately, metronidazole is often poorly tolerated due 
to side effects, including gastrointestinal upset, alcohol intolerance, metallic taste, 
and infrequently neurological and or hematological adverse reactions. In addition, 
cure rates associated with this treatment are low (as low as 61% one month after 
therapy) 51 and there is a high incidence of overgrowth of pathogenic bacteria 
after treatment. 
                The loss of vaginal lactobacilli appears to be the major factor in the 
cascade of changes leading to bacterial vaginosis52 and relapses are associated 
with failure to establish healthy lactobacilli dominated vaginal flora. The ways in 
which vaginal lactobacillus flora can be optimized are by using pessaries to 
deliver lactobacillus directly in to the vagina or oral supplementation with 
lactobacillus probiotics which can colonize in the vagina. 
                  Several studies have been conducted to evaluate the efficacy of 
different probiotic lactobacillus strains in the treatment of bacterial vaginosis. 
                  A study showed that vaginal douching with yoghurt was ineffective in 
the treatment of bacterial vaginosis as the lactobacilli in yoghurt failed to colonise 
in the vagina.53 
         15  
                     In a double blind, placebo-controlled study, 60 women with bacterial 
vaginosis were randomised to receive vaginal suppositories of either lyophilized 
Lactobacillus acidophilus or placebo. 16 out of 28 women who were treated with 
lactobacilli had normal vaginal wet smear results, in comparison to none of the 
29 women treated with placebo. Only three of the women who received the 
Lactobacillus suppository were free of bacterial vaginosis after the subsequent 
menstruation.54 
                         In a clinical trial conducted in 32 women with BV in the first 
trimester of pregnancy, intravaginal application of yoghurt was found to be 
effective in the treatment and prevention of bacterial vaginosis at two month 
follow up.55This study concluded that probiotics may be used as an alternative to 
antimicrobials to resolve BV in pregnancy. 
                     L. rhamnosus GR-1 and L. reuteri RC-14 was found to adhere to 
uroepithelial cells to inhibit the growth and adhesion of uropathogens. 39These 
two strains were the first oral probiotic supplementation for restoration and 
maintenance of a healthy vaginal flora. 
                   In a study conducted in 10 women with recurrent yeast vaginitis, 
bacterial vaginosis and urinary tract infections, strains Lactobacillus rhamnosus 
GR-1 and Lactobacillus fermentum RC-14 suspended in skim milk were given 
twice daily for 14 days, were recovered from the vagina and identified by 
morphology and molecular typing within 1 week of commencement of therapy. 
Six cases of BV were resolved within 1 week of therapy. 56 
16             
                     A randomised, placebo-controlled trial of 64 healthy women given 
daily oral capsules of Lactobacillus rhamnosus GR-1 and Lactobacillus 
fermentum RC-14 for 60 days showed no adverse effects. Microscopy analysis 
showed restoration from asymptomatic bacterial vaginosis microflora to a normal 
lactobacilli colonized microflora in 37% women during lactobacilli treatment 
compared to 13% on placebo. Lactobacilli were detected in more women in the 
lactobacilli-treated group than in the placebo group at 28 day and 60-day. The 
combination of probiotic L. rhamnosus GR-1 and L. fermentum RC-14 reduced 
the colonization of the vagina by potential pathogenic bacteria and yeast .57 
VULVOVAGINAL CANDIDIASIS 
                    Approximately 75% of women are diagnosed to have vulvovaginal 
candidiasis at least once, and of those, about 50% have a recurrence.58 Candida 
yeasts reside in the mouth, gastrointestinal tract, and vagina without causing 
symptoms. Symptoms develop only when Candida becomes overgrown in these 
sites. Rarely, Candida is transmitted from person to person through sexual 
intercourse. 58 
                      Candida albicans is responsible for 80 to 92 percent of episodes of 
vulvovaginal candidiasis.59Recently, an increased frequency of other candida 
species, particularly C. glabrata, has been reported, 60 possibly due to 
widespread use of over-the-counter drugs, long-term use of suppressive azoles, 
and the use of short courses of antifungal drugs. Sporadic attacks of vulvovaginal  
 
  
 
Figure-5 -- 10% Potassium hydroxide preparation of vaginal smear. 
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candidiasis usually occur without an identifiable precipitating factor, except in 
patients with uncontrolled diabetes. Patients with vulvovaginal candidiasis have 
vaginal discharge, which is classically white, creamy, and curdy (cottage cheese-
like) in appearance, adherent to the epithelium and associated with itching, 
burning, irritation, edema, erythema and or excoriation of the vagina or vulva. 61 
A screening 10% Potassium hydroxide preparation from the inflamed vaginal 
mucosa reveals yeast forms (hyphae/pseudohyphae) or budding yeasts as 
shown in figure-5. Topical azole and oral fluconazole are equally efficacious in 
the management of vulvovaginal candidiasis. 61  
                     There is little evidence that probiotics can effectively cure a 
symptomatic yeast vaginitis. 
              A crossover one year study in which 33 patients with a history of 
recurrent yeast vaginitis ( 5 per year) were given eight ounces of L acidophilus 
supplemented yoghurt daily for six months then switched to a yoghurt-free diet, 
resulted in 0.4 breakthrough infections compared with 2.5 per study term.62 
                The significant reduction in number of positive cultures for candida was 
consistent with the use of L rhamnosus GR-1 and L fermentum RC-14 in 
lyophilized capsule form, which showed up to one log fewer yeast recovered from 
the vagina during treatment compared with baseline.57 
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URINARY TRACT INFECTION 
 
                    Worldwide, every year it is estimated that several hundred million 
women suffer from UTI especially from lower UTI, which is the infection of the 
urethra and urinary bladder. Urinary tract infections are defined by the presence 
of viable microorganisms within the urinary tract and are usually caused by 
Gram-negative aerobic organisms originating from the gut flora.63 
                     Symptoms of urinary tract infection (UTI) include fever, frequency 
and urgency of micturition, dysuria, foul-smelling urine, supra pubic pain, 
vomiting, irritability and scalding pain in the urethra during micturition. The 
conventional treatment for UTI is antibiotics. Unfortunately, the infection usually 
recurs (27-48%) once the antibiotic regimen has ended, as bacterial adherence 
of uropathogens is not altered by the antibiotics. 38 
                     Extensive studies of various lactobacilli strains and the properties 
believed to be important for protecting the host, led to selection of a two-strain 
combination for vaginal use. This comprised of distal urethral isolate L 
rhamnosus GR-1, selected primarily for its anti-Gram negative activities and 
resistance to spermicide, and L fermentum B-54, replaced more recently by RC-
14, for anti-Gram positive cocci activities and hydrogen peroxide production. In 
order to optimise a consistent dose with a good shelf life in a formulation 
preferred by patients, the organisms were freeze dried and placed in gelatin 
capsules, with dosage at 109 per capsule.64  
 
19 
                     Results from various studies indicate that the recurrence rate of UTI 
was significantly reduced after using one or two capsules vaginally per week for 
one year, with no side effects or yeast infections.64 The rate of infection was the 
same as those found in studies using daily antibiotics for one year.65       
             
                         After going through these references, we decided to 
evaluate the efficacy and tolerability of two-strain combination of oral probiotics - 
Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 as integral 
therapy with conventional treatment in the following female urogenital infections - 
 Bacterial vaginosis (BV), 
 Vulvovaginal candidiasis (VVC or yeast vaginitis), and 
 Urinary tract infection (UTI). 
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STUDY OBJECTIVES 
 
 
 To evaluate the efficacy of probiotics as integral therapy with 
conventional treatment in the following female urogenital infections  
 
 Bacterial vaginosis (BV), 
 Vulvovaginal candidiasis (VVC or yeast vaginitis), and 
 Urinary tract infection (UTI). 
 
 
 To evaluate the tolerability of probiotics. 
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STUDY   METHODOLOGY 
 Study   Centre 
                        Department of Female Urology and Urogynaecology,  
Government Kasturba Gandhi Hospital for Women and Children, Triplicane, 
Chennai -5. 
Study Design 
                     Randomised, Double blind, Comparative, 
                                        Prospective, Parallel   group   study. 
 Study Phase  
                       Phase - IV- Clinical Study. 
 Study   Duration 
                      Eight weeks. 
Study Period 
                September 2005 to August 2006. 
Study Population 
 
 
                       Patients attending the outpatient clinic of the Department of 
Female Urology and Urogynaecology, Government Kasturba Gandhi Hospital for 
Women and Children with urinary tract infections, bacterial vaginosis or vulvo 
vaginal candidiasis fulfilling the recruitment criteria were considered for the study.  
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Ethical Requirement 
 
                        The study was performed in accordance with the principles stated 
in the Declaration of Helsinki. Ethical approval of the study protocol was obtained 
from the Ethics Committee at the Institution before the study was undertaken. 
Informed Consent 
 
                         Written informed consent was obtained from each patient in the 
prescribed format prior to performance of any study related procedures: before 
physical examination, laboratory screening or any other investigational procedure 
and before administration of any study related medication. The patients were 
given full information about the nature, procedure and importance of the study. If 
the patient was illiterate, an impartial witness (a person, who was independent of 
the trial and who cannot be unfairly influenced by people involved in the trial) 
attended the informed consent process and read out and explained the 
procedure to the patient in a language known to the patient.  
Inclusion Criteria 
 Females in the reproductive age group from 18 to 45   years. 
 Patients with history of symptoms consistent with diagnosis of bacterial 
vaginosis like abnormal, profuse, white and homogenous vaginal 
discharge confirmed by an elevated vaginal pH >4.5 and Gram staining 
of vaginal discharge showing few or absent lactobacilli (long Gram 
positive rods) with greatly increased number of small Gram negative or 
Gram variable rods or both.  
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 Patients with history of symptoms consistent with diagnosis of 
vulvovaginal candidiasis like itching, burning, irritation, edema and or 
excoriation of the vagina or vulva with a white, creamy and curdy 
(cottage cheese like) vaginal discharge confirmed by 10% KOH 
preparation revealing yeast forms (Hyphae or pseudohyphae or 
budding yeasts). 
 Patients with history of symptoms consistent with diagnosis of lower 
urinary tract infections (UTI) like fever, frequency and urgency of 
micturition, dysuria, foul-smelling urine, supra pubic pain, vomiting, 
irritability and scalding pain in the urethra   during micturition and the 
clinical diagnosis confirmed by microscopic examination of urine and 
mid stream urine culture positive for pathogenic bacteria. 
Exclusion Criteria 
 
 Pregnant   and   lactating   women. 
 Patients with history of   antibiotic   administration    in   the past 
one month. 
 Patients with history   of   probiotic or   synbiotic   administration   in   
the past three   months.    
 Patients with history   of   vaginal   discharge   due to   other causes 
like stricture, fistula, congenital   abnormality and malignancy. 
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 Patients with clinically significant renal, hepatic, cardiovascular, 
haematopoetic, pulmonary, gastrointestinal, nervous or endocrine   
disorders except   uncomplicated diabetes mellitus. 
 Patients    with   history   of   surgery   in   urogenital   system 
except   episiotomy and tubectomy. 
 Patients    with   vaginal or cervical smear negative for pathogenic   
organisms. 
Laboratory   Investigations      
• Complete Haemogram: Haemoglobin, Total count, Differential 
count, Platelet count and Erythrocyte sedimentation rate. 
•  Routine Urine Analysis: Albumin, sugar and microscopic 
examination of urine for white blood cells, red blood cells and 
casts. 
• Midstream Urine Colony count and Culture-Sensitivity:  for 
patients   with   urinary   tract   infection. 
• Vaginal or cervical swab or smear examination:   
       GRAM STAIN -- NUGENT’S SCORE 
                             10% Potassium hydroxide vaginal smear preparation. 
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• Vaginal pH monitoring: 
   A cotton-tipped swab was touched to the sidewall of the 
vagina midway between the introitus and the cervix and 
brought in contact with a pH paper (expanded in the range of 
3.6 to 6.1 pH). The colour developed in the pH paper was 
compared with a standard pH paper indicator chart. 
    Vaginal pH >4.5 is consistent with BV. 
• Blood Chemistry: 
 Blood Sugar, Blood Urea, Serum Creatinine, Serum            
bilirubin, SGOT, SGPT, Serum alkaline phosphatase, Serum 
total proteins. 
• Ultrasound Abdomen   
Study Procedures      
Visit I -Screening                                                                                  
                         Patients attending the outpatient clinic of the Department of 
Female Urology and Urogynaecology, Government Kasturba Gandhi Hospital for 
Women and Children with symptoms of urinary tract infections, bacterial 
vaginosis or vulvovaginal candidiasis were screened. The patients were given 
the informed consent form and were asked to read it completely. If they were 
satisfied, they were asked to sign in the informed consent form. During 
screening, a complete examination was done which included detailed medical 
history and physical examination. All patients underwent urogenital   examination  
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in which examination   of   vagina, cervix and external   urethra   was done. 
Vaginal or cervical smear was taken   and   sent for laboratory analysis. Vaginal 
pH was monitored. Nugent score for bacterial vaginosis was done. In 
vulvovaginal candidiasis, clinical assessment was based on composite 
signs/symptoms score in which each evaluated sign and/or symptom like itching, 
burning, irritation, edema, erythema and/or excoriation of the vagina/vulva were 
given a numerical rating based on severity (absent = 0; mild = 1; moderate = 2; 
severe = 3). Complete haemogram and blood chemistry was done for all the 
patients. Midstream urine routine analysis, colony count and culture-sensitivity 
were done. Ultrasound abdomen was done for all patients to rule out kidney, 
urinary bladder, uterine and ovarian abnormalities (congenital or pathological). 
The patients were instructed to return after 2 days. 
Visit- II- Recruitment                                                                             
                   The laboratory results were analysed with the clinical features and 
physical examination. Those who fulfilled the inclusion criteria were recruited for 
the study. Demographic details like address and contact number were recorded. 
Patients were divided in to three groups based on the type of urogenital infection. 
                   Patients with confirmed diagnosis of bacterial vaginosis were 
assigned to Group I. Patients with confirmed diagnosis of vulvovaginal 
candidiasis were assigned to Group II. Patients with confirmed diagnosis of 
urinary tract infection were assigned to Group III.  
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• Randomisation to probiotic or placebo 
                                     Patients of each group (Group I- BV; Group II – VVC; 
Group III –UTI) were randomly assigned to receive either of the two study 
therapies –either integral therapy of probiotics with conventional treatment or 
placebo with conventional treatment.  
 Patients with bacterial vaginosis (Group I) received metronidazole 400 mg 
orally twice daily for one week and randomly assigned to receive probiotic 
or placebo 150 mg capsules twice daily for eight weeks. 
 Patients with vulvovaginal candidiasis (Group II) received clotrimazole 1% 
vaginal cream applied 5 gm intravaginally per day for one week and 
randomly assigned to receive probiotic or placebo 150 mg capsules twice 
daily for eight weeks. 
 Patients with urinary tract infection (Group III) received the appropriate 
sensitive antibacterial for one week and randomly assigned to receive 
probiotic or placebo 150 mg capsules twice daily for eight weeks. 
The study drugs were supplied by Tablets India Limited. The probiotic and 
placebo capsules were matched for size, shape and volume of contents. The 
placebo was microcrystalline cellulose. The study was a double blind 
comparative study. No patient was entered more than once in the study. Each 
patient was randomised after ensuring that recruitment criteria are met.  
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                     Study medication according to the randomised schedule was issued 
for 2 weeks. Patients were instructed to report to the outpatient clinic of the 
Department of Female Urology and Urogynaecology, Government Kasturba 
Gandhi Hospital for women and children after 2 weeks along with the empty 
medication bottle. 
Follow up 
           Urogenital examination and clinical assessment of symptoms were done 
at the end of week 2, week 4, week 6 and at the end of week 8. Study medication 
according to the randomised schedule was issued every 2 weeks.                
Adverse event if any, observed or reported by the patients were recorded.  
           Apart from routine urogynaecological examination and symptom 
assessment, the following were done at the end of 4th and 8th week. 
• For patients with Bacterial vaginosis (Group I), vaginal pH 
monitoring and Gram staining of vaginal smear for Nugent 
scoring were done. 
• For patients with vulvovaginal candidiasis (Group II), vaginal pH 
monitoring, 10% KOH preparation of vaginal smear and 
composite sign/symptom score were done. 
• For patients with urinary tract infection (Group III), routine urine 
analysis, colony count and culture-sensitivity were done. 
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                    Complete blood count, blood sugar, blood urea, serum creatinine, 
serum bilirubin, SGOT, SGPT, serum alkaline phosphatase and serum total 
proteins were done   at   the   end   of     eighth   week in all the treatment groups. 
Patients were advised to report to the outpatient clinic of the study centre if they 
had recurrence of symptoms after completion of study. 
Withdrawal and dropouts 
                   Patients were withdrawn from the study by the physician if any 
adverse effect was observed. For all patients who dropped out of the study, 
efforts were made to ascertain the reason for dropout. 
 
Decoding was done at the end of the study. 
 
Statistical report 
                   Data were analysed using SPSS 11.5. Descriptive analysis for non-
parametric variables was expressed in proportion and parametric variables in 
mean and standard deviation. The treatment difference was assessed using t 
test for independent samples for parametric variables and by Chi square test for 
non-parametric variables. Statistical significance was assessed using p at 0.05 
cut off or 95% confidence interval. (95% CI). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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RESULTS 
                       A total of 580 patients were screened for the study. Among them, 
252 patients were enrolled. Only 122 patients fulfilled the inclusion criteria and 
were divided in to three groups based on the type of urogenital infection - 
 GROUP I: Patients with bacterial vaginosis (50 patients), 
 GROUP II: Patients with vulvovaginal candidiasis (30 patients), 
 GROUP III:  Patients with urinary tract infection (42 patients). 
                         Patients of each group were randomly allocated to subgroups A 
or B to receive either of the two study therapies –either integral therapy of 
probiotics with conventional treatment (subgroup A) or placebo with 
conventional treatment (subgroup B). Each 150mg capsule of the probiotic 
mixture had a minimum of 5 billion CFU of Lactobacillus rhamnosus GR-1 and 
Lactobacillus reuteri RC-14 in equal proportions. The placebo was 
microcrystalline cellulose.  Twenty-four patients of group IA and twenty-three 
patients of group IB completed the study. Fifteen patients of group II A and fifteen 
patients of group II B completed the study. Twenty-one patients of group III A and 
twenty patients of group III B completed the study. There were four-drop outs (1 
patient in group IA, 2 patients in group I B and 1 patient in group III B). Drop out 
patients of group I A, III B and one patient of group I B refused to take the 
medication and did not return after the second visit. One patient of group I B had 
intercurrent illness and discontinued from the intervention. The following flow 
chart explains the progress of participants through the trial. 
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                  R A N D O M I S A T I O N 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                 
 
PATIENTS SCREENED (580) 
GROUP I      
PATIENTS WITH 
BACTERIAL 
VAGINOSIS 
(50 PATIENTS) 
GROUP II    
PATIENTS WITH 
VULVOVAGINAL 
CANDIDIASIS 
(30 PATIENTS)        
 
GROUP III      
PATIENTS WITH 
URINARY TRACT 
INFECTIONS 
 (42  PATIENTS)      
 
INTEGRAL THERAPY OF  
 PROBIOTICS WITH CONVENTIONAL TREATMENT (SUBGROUP A) 
OR 
PLACEBO WITH CONVENTIONAL TREATMENT (SUBGROUP B) 
STUDY DRUG TREATMENT FOR 8 WEEKS. 
 
PATIENTS ENROLLED (252) 
PATIENTS SELECTED (122) 
GROUP IA – 25 patients. 
24 patients completed 
study; DROPOUT- I patient 
GROUP IB –25 patients.  
 23 patients completed 
study; DROPOUT- 2 patients.      
GROUP  IIA- 15 patients 
completed  study. 
GROUP  IIB - 15patients 
completed  study .     
GROUP IIIA-21 patients 
      21 patients completed 
study 
GROUP IIIB  -  21 patients 
      20 patients completed 
study; Dropout- 1 patient.    
GROUP-I-BACTERIAL VAGINOSIS 
DEMOGRAPHIC FEATURES 
 
Table 2- Age distribution 
95% 
Confidence 
Interval of the 
Difference 
Drug 
Group 
No. of 
patients 
Mean 
Age 
Std. 
Deviation 
 
P 
Mean 
Difference 
Lower Upper 
Probiotic 
Group IA 
24 32.7 6.4 
 
Placebo 
Group IB 
23 31.6 5.5 
 
0.52 
 
1.14 
 
-2.37 
 
4.66 
 
Figure 6- Mean age distribution 
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Table-2 shows 
• The number of bacterial vaginosis patients (group I) in probiotic (group IA) 
and placebo subgroups (group I B).  
• The mean age of patient in probiotic (group IA) and placebo subgroup 
(group I B). 
• The mean age of patient in probiotic  (group IA) subgroup was 32.7 
• The mean age of patient in placebo subgroup (group I B) was 31.6 
• The difference between the probiotic (group IA) and placebo subgroups 
(group I B) was not statistically significant (95% confidence interval, -2.37 
to 4.66; p= 0.52). 
 
 
 
 
Figure-6 is the diagrammatic representation of the mean age distribution in the 
probiotic and placebo groups. 
 
 
 
 
 
 
Table 3 –Comparison of mean vaginal pH 
 
 
Figure 7–Comparison of mean vaginal pH 
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95% 
Confidence 
Interval of the 
Difference 
Visits Drug 
Group 
Mean 
vaginal 
pH 
Std. 
Deviation 
p Mean 
Difference 
Lower Upper 
Probiotic 5.4 0.4 Baseline 
Placebo 5.3 0.3 
0.36 
 
 
0.09 -0.11 0.29 
Probiotic 5.1 0.5 After 4 
weeks  Placebo 5.1 0.5 
0.64 
-0.07 -0.36 0.23 
Probiotic 4.8 0.4 After 8 
weeks Placebo 5.1 0.4 
0.00 -0.36 -0.58 -0.14 
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Table 3 –shows 
• The mean vaginal pH in the probiotic and placebo groups at baseline and 
after 4 weeks and 8 weeks of study therapy. 
•  The difference in mean vaginal pH between the probiotic and placebo 
groups at the baseline was not statistically significant (95% confidence 
interval, -0.11 to 0.29; p= 0.36). 
• The difference in mean vaginal pH between the probiotic and placebo 
groups after 4 weeks of study therapy was not statistically significant (95% 
confidence interval, -0.36 to 0.23; p= 0. 64). 
• The difference in mean vaginal pH between the probiotic and placebo 
groups after 8 weeks of study therapy was statistically significant (95% 
confidence interval, -0.58 to 0.14; p= 0. 00). 
 
 
Figure 7 – is the diagrammatic representation of the mean vaginal pH in the 
probiotic and placebo groups at baseline and after 4 weeks and 8 weeks of 
study therapy. 
 
 
 
 
 
Table-4 - Comparison of mean Nugent score 
                        
95% 
Confidence 
Interval of the 
Difference 
Visits Drug 
Group 
Mean 
Nugent 
score 
Std. 
Deviation 
p Mean 
Difference 
Lower Upper 
Probiotic 8.5 1.1 Baseline 
Placebo 8.5 1.1 
 
0.95 
 
-0.02 -0.66 0.62 
Probiotic 5.5 1.4 After 4 
weeks  Placebo 6.6 1.0 
0.00 
-1.15 -1.88 -0.42 
Probiotic 4.6 1.1 After 8 
weeks Placebo 5.4 1.4 
0.03 -0.81 -1.56 -0.06 
 
Figure-8 - Comparison of mean Nugent score 
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Table 4 –shows 
• The mean Nugent score in the probiotic and placebo groups at baseline 
and after 4 weeks and 8 weeks of study therapy. 
•  The difference in mean Nugent score between the probiotic and placebo 
groups at the baseline was not statistically significant (95% confidence 
interval, -0.66 to 0.62; p= 0.95). 
• The difference in mean Nugent score between the probiotic and placebo 
groups after 4 weeks of study therapy was statistically significant (95% 
confidence interval,  -1.88 to -0.42; p= 0. 00). 
• The difference in mean Nugent score between the probiotic and placebo 
groups after 8 weeks of study therapy was statistically significant (95% 
confidence interval, -1.56 to –0.06; p= 0. 03). 
 
 
Figure 8 – is the diagrammatic representation of the mean Nugent score in 
the probiotic and placebo groups at baseline and after 4 weeks and 8 weeks 
of study therapy. 
 
 
 
 
 
 
 
 Table 5 – Comparison of frequency of vaginal discharge characteristic of 
bacterial vaginosis. 
 
Group 
Probiotic Placebo 
Variable No of subjects % No of subjects % Total Chi Square p 
Present 24 100% 23 100% 47 
Baseline Absent 0 0% 0 0% 0 NA NA 
Present 6 25% 11 47.8% 17 
4 Weeks Absent 18 75% 12 52.2% 30 2.65 0.1 
Present 3 12.5% 11 47.8% 14 
8 Weeks Absent 21 87.5% 12 52.2% 33 7.01 0.008 
 
 
 
 
Figure 9-Comparison of percentage of patients with characteristic vaginal 
discharge of bacterial vaginosis. 
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Table 5 shows 
• The number and percentage of patients in probiotic and placebo groups 
with characteristic vaginal discharge of bacterial vaginosis. 
• The treatment difference was assessed using Chi square test. 
• At baseline, all the patients of probiotic and placebo group had vaginal 
discharge characteristic of bacterial vaginosis. 
• There was no significant difference in the frequency of vaginal discharge 
characteristic of bacterial vaginosis between the probiotic and placebo 
groups at 4 weeks of study therapy (p=0.1). 
• There was a statistically significant difference in the frequency of vaginal 
discharge characteristic of bacterial vaginosis between the probiotic and 
placebo groups at 8 weeks of study therapy (p=0.008). 
 
 
 
Figure 9- represents a diagrammatic representation of comparison of percentage 
of observed characteristic vaginal discharge of bacterial vaginosis in probiotic 
and placebo groups at baseline, and after 4 weeks and 8 weeks of study therapy. 
 
 
  
 
 
 
 
 
 
  
Table 6 – Comparison of frequency of foul smelling odor of vaginal 
discharge. 
 
Group 
Probiotic Placebo 
Variable No of subjects % No of subjects % Total Chi Square p 
Present 24 100% 23 100% 47 
Baseline Absent 0 0% 0 0% 0 NA NA 
Present 4 16.7% 7 30.4% 11 
4 Weeks Absent 20 83.3% 16 69.6% 36 1.24 0.26 
Present 2 8.3% 7 30.4% 9 
8 Weeks Absent 22 91.7% 16 69.6% 38 3.706 0.054 
 
 
 
Figure 10-Comparison of percentage of patients with characteristic foul- 
smelling odor of vaginal discharge in the study groups. 
 
100%
16.70%
8.30%
100%
30.40% 30.40%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Baseline 4 weeks 8 weeks
Visit
Pe
rc
en
ta
ge
Probiotic
Placebo
 
 
 
36 
 
Table 6 shows 
• The number and percentage of patients in probiotic and placebo groups 
with foul smelling odor of vaginal discharge. 
• The treatment difference was assessed using Chi square test. 
• At baseline, all the patients of probiotic and placebo group had foul 
smelling odor of vaginal discharge. 
• There was no significant difference in the frequency of foul smelling odor 
of vaginal discharge between the probiotic and placebo groups at 4 weeks 
of study therapy (p=0.26). 
• The difference in the frequency of foul smelling odor of vaginal discharge 
between the probiotic and placebo groups at 8 weeks of study therapy 
was not significant (p=0.054). 
 
 
Figure 10- represents a diagrammatic representation of comparison of 
percentage of patients with foul smelling odor of vaginal discharge in probiotic 
and placebo groups at baseline, and after 4 weeks and 8 weeks of study therapy. 
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Table 7 
 
Variables Group Mean Std. Deviation 
 
 
p 
Probiotic 25.5 2.9 Blood Urea 
Baseline Placebo 25.5 2.8 
0.98 
 
Probiotic 24.9 2.9 Blood Urea 8 
Wks Placebo 24.7 2.3 
 
0.82 
Probiotic 96.8 15.4 Blood Sugar 
Baseline Placebo 99.5 15.0 
 
0.54 
Probiotic 95.67 15.16 Blood Sugar 
8 Wks Placebo 104.20 15.74 
 
0.71 
Probiotic 0.7 0.1 SrCreatinine 
Baseline Placebo 0.8 0.1 
 
0.57 
Probiotic 0.8 0.2 SrCreatinine 
8 Wks Placebo 0.8 0.1 
0.83 
 
Probiotic 18.9 2.7 SGOT 
Baseline Placebo 18.4 2.8 
0.55 
Probiotic 19.0 2.3 SGOT 
8 Wks Placebo 18.2 2.2 
0.24 
Probiotic 13.3 2.5 SGPT 
Baseline Placebo 12.8 2.6 
0.54 
Probiotic 13.3 2.3 SGPT 
8 Wks Placebo 12.9 2.1 
0.56 
Probiotic 6.0 0.2 TotProt 
Baseline Placebo 5.9 0.1 
0.20 
Probiotic 6.0 0.2 TotProt 
8 Wks Placebo 5.9 0.2 
0.29 
 
 
The above table depicts the difference between probiotic and placebo groups in 
blood urea, blood sugar, serum creatinine, SGOT, SGPT and total proteins taken 
at baseline and end of 8 weeks. By independent samples t test, the difference 
between the treatment groups was not statistically significant (p value > 0.05). 
 GROUP-II-VULVOVAGINAL CANDIDIASIS 
Demographic features 
Table 8- Mean age distribution 
95% 
Confidence 
Interval of the 
Difference 
Drug 
Group 
No. of 
patients 
Mean 
Age 
Std. 
Deviation 
P Mean 
Difference 
Lower Upper 
Probiotic 15 29.73 5.98 
Placebo 15 30.27 6.73 
 
0.82 
 
-0.53 
 
-5.30 
 
4.23 
 
Figure 11- Mean age distribution 
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Table-8 shows 
• The number of patients with vulvovaginal candidiasis (group II) in probiotic 
(group IIA) and placebo subgroups (group II B).  
• The mean age of patient in probiotic (group IIA) and placebo subgroup 
(group II B). 
• The mean age of patient in probiotic  (group IIA) subgroup was 29.73 
• The mean age of patient in placebo subgroup (group II B) was 30.27 
• The difference between the probiotic (group IIA) and placebo subgroups 
(group II B) was not statistically significant (95% confidence interval, -5.30 
to 4.23; p= 0.82). 
 
 
 
Figure-11 is the diagrammatic representation of the mean age distribution in the 
probiotic and placebo groups 
 
 
 
 
 
 
 
 
 
 
 
Table 9 –Comparison of mean  vaginal pH 
 
95% 
Confidence 
Interval of the 
Difference 
Visits Drug 
Group 
Mean 
vaginal 
pH 
Std. 
Deviation 
p Mean 
Difference 
Lower Upper 
Probiotic 4.17 0.24 Baseline 
Placebo 4.20 0.25 
 
0.72 
 
 
-0.03 -0.22 0.15 
Probiotic 4.17 0.24 After 4 
weeks  Placebo 4.20 0.25 
0.72 
 
-0.03 -0.22 0.15 
Probiotic 4.23 0.26 After 8 
weeks Placebo 4.17 0.24 
 
0.07 
 
0.07 -0.12 0.25 
 
Figure 12 –Comparison of mean vaginal pH 
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Table 9 –shows 
• The mean vaginal pH in the probiotic and placebo groups at baseline and 
after 4 weeks and 8 weeks of study therapy. 
•  The difference in mean vaginal pH between the probiotic and placebo 
groups at the baseline was not statistically significant (95% confidence 
interval, -0.22 to 0.15; p= 0.72). 
• The difference in mean vaginal pH between the probiotic and placebo 
groups after 4 weeks of study therapy was not statistically significant (95% 
confidence interval, -0.22 to 0.15; p= 0. 72). 
• The difference in mean vaginal pH between the probiotic and placebo 
groups after 8 weeks of study therapy was not statistically significant (95% 
confidence interval, -0.12 to 0.25; p= 0. 07). 
 
Figure 12 – is the diagrammatic representation of the mean vaginal pH in the 
probiotic and placebo groups at baseline and after 4 weeks and 8 weeks of 
study therapy. 
 
 
 
 
 
 
 
  
Table 10- Comparison of mean composite sign/ symptom score in VVC. 
 
95% 
Confidence 
Interval of the 
Difference 
Visits Drug 
Group 
Mean Std. 
Deviation 
P Mean 
Difference 
Lower Upper 
Probiotic 9.20 1.37 Baseline 
Placebo 8.73 1.53 
 
0.39 
 
0.47 -0.62 1.56 
Probiotic 3.80 1.74 After 4 
weeks  Placebo 3.60 1.18 
0.72 0.20 -0.91 1.31 
Probiotic 1.80 1.26 After 8 
weeks Placebo 2.00 1.69 
 
0.72 -0.20 -1.32 0.92 
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Figure 13 - Comparison of mean composite sign/ symptom score in VVC. 
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Table 10–shows 
• The mean composite sign/ symptom score in the probiotic and placebo 
groups at baseline and after 4 weeks and 8 weeks of study therapy. 
•  The difference in mean composite sign/ symptom score between the 
probiotic and placebo groups at the baseline was not statistically 
significant (95% confidence interval, -0.62 to 1.56; p= 0.39). 
• The difference in mean composite sign/ symptom score between the 
probiotic and placebo groups after 4 weeks of study therapy was not 
statistically significant (95% confidence interval,  -0.91 to 1.31; p= 0. 72). 
• The difference in mean composite sign/ symptom score between the 
probiotic and placebo groups after 8 weeks of study therapy was not 
statistically significant (95% confidence interval, -1.32 to –0.92; p= 0. 72). 
 
 
Figure 13 – is the diagrammatic representation of the mean composite sign/ 
symptom score in the probiotic and placebo groups at baseline and after 4 
weeks and 8 weeks of study therapy. 
 
 
 
 
 Table 11- Comparison of frequency of potassium hydroxide (KOH) 
preparation of vaginal smear 
 
KOH 
  
Probiotic Placebo 
Variable Group Count % Count % Total Chi-Square P 
Positive 15 100 % 15 100 % 30 
Baseline Negative 0 0 0 0 0 0 Not sig 
Positive 7 46.7% 9 60 % 16 
KOH 4 wks Negative 8 53.3% 6 40 % 14 0.54 Not sig 
Positive 7 46.7% 9 60 % 16 
KOH 8 wks Negative 8 53.3% 6 40 % 14 0.54 Not sig 
 
Figure 14- Comparison of percentage of patients with KOH preparation of 
vaginal smear positive for Candida. 
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Table 11 shows 
• The number and percentage of patients in probiotic and placebo groups 
with KOH preparation of vaginal smear positive or negative for candida. 
• The treatment difference was assessed using Chi square test. 
• At baseline, all the patients of probiotic and placebo group had KOH 
preparation of vaginal smear positive for candida. 
• There was no significant difference in the frequency of KOH preparation of 
vaginal smear positive for candida between the probiotic and placebo 
groups at 4 weeks of study therapy (p=0.54). 
• There was no significant difference in the frequency of KOH preparation of 
vaginal smear positive for candida between the probiotic and placebo 
groups at 8 weeks of study therapy (p=0.54). 
 
 
Figure 14 - represents a diagrammatic representation of comparison of 
percentage of patients in probiotic and placebo groups with KOH preparation of 
vaginal smear positive for candida at baseline, and after 4 weeks and 8 weeks of 
study therapy. 
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Table- 12  
 
 
Variables Group Mean 
Std. 
Deviati
on 
 
 
p 
Probiotic 24.53 2.20 Blood Urea 
Baseline Placebo 23.33 2.02 
 
0.13 
 
Probiotic 24.27 1.83 Blood Urea  
8 Wks Placebo 23.87 2.33 
 
0.60 
Probiotic 95.67 15.16 Blood Sugar 
 Baseline Placebo 104.20 15.74 
 
0.14 
Probiotic 99.73 9.76 Blood Sugar 
8 Wks Placebo 101.07 9.65 
 
0.71 
Probiotic 0.69 0.09 SrCreatinine 
Baseline Placebo 0.71 0.10 
0.70 
 
Probiotic 0.69 0.10 SrCreatinine 
8 Wks Placebo 0.69 0.07 
1.00 
 
Probiotic 18.9 2.7 SGOT 
Baseline Placebo 18.4 2.8 
0.55 
Probiotic 19.0 2.3 SGOT 
8 Wks Placebo 18.2 2.2 
0.24 
Probiotic 13.3 2.5 SGPT 
Baseline Placebo 12.8 2.6 
0.54 
Probiotic 13.3 2.3 SGPT 
8 Wks Placebo 12.9 2.1 
0.56 
Probiotic 5.97 0.15 TotProt 
Baseline Placebo 5.95 0.13 
0.70 
Probiotic 5.94 0.12 TotProt 
8 Wks Placebo 5.91 0.13 
0.47 
 
 
 
The above table depicts the difference between probiotic and placebo groups in 
blood urea, blood sugar, serum creatinine, SGOT, SGPT and total proteins taken 
at baseline and end of 8 weeks. By independent samples t test, the difference 
between the treatment groups was not statistically significant (p value > 0.05). 
 
 
 
GROUP-III URINARY TRACT INFECTION 
Demographic features 
Table 13- Mean age distribution 
95% Confidence 
Interval of the 
Difference 
Drug 
Group 
No. of 
patients 
Mean 
Age 
Std. 
Deviation 
P Mean 
Difference 
Lower Upper 
Probiotic 21 35.0 6.9 
Placebo 20 36.1 5.4 0.57 -1.10 -5.02 2.83 
 
 
Figure 15- Mean age distribution 
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Table-13 shows 
• The number of patients with urinary tract infection (group III) in probiotic 
(group IIIA) and placebo subgroups (group III B).  
• The mean age of patient in probiotic (group IIIA) and placebo subgroup 
(group III B). 
• The mean age of patient in probiotic  (group IIIA) subgroup was 35.0 
• The mean age of patient in placebo subgroup (group III B) was 36.1 
• The difference between the probiotic (group IIIA) and placebo subgroups 
(group III B) was not statistically significant (95% confidence interval, -5.02 
to 2.83; p= 0.57). 
 
 
 
Figure-15 is the diagrammatic representation of the mean age distribution in the 
probiotic and placebo groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14:  Comparison of frequency of occurrence of fever 
 
 
Group 
Probiotic Placebo 
Variable Number % Number % Total 
Chi 
Square p 
Present 21 100.0% 20 100.0% 41 
Baseline Absent 0 0.0% 0 0.0% 0 NA NA 
Present 1 4.8% 1 5.0% 2 
4 Weeks Absent 20 95.2% 19 95.0% 39 0.001 0.97
Present 0 0.0% 0 0.0% 0 
8 Weeks Absent 21 100.0% 20 100.0% 41 NA NA 
 
 
Figure 16:  Comparison of percentage of patients with fever 
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Table 14 shows 
• The number and percentage of patients in probiotic and placebo groups 
with fever. 
• The treatment difference was assessed using Chi square test. 
• At baseline, all the patients of probiotic and placebo group had fever. 
• There was no significant difference in the frequency of fever between the 
probiotic and placebo groups at 4 weeks of study therapy (p=0.97). 
• After 8 weeks of study therapy, there was no report of fever by any patient 
in probiotic or placebo group. 
 
 
Figure 16- represents a diagrammatic representation of percentage of patients 
with fever in probiotic and placebo groups at baseline, and after 4 weeks and 8 
weeks of study therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 15:  Comparison of frequency of occurrence of dysuria. 
 
Group 
Probiotic Placebo 
Variable Number % Number % Total 
Chi 
Square p 
Present 21 100.0% 20 100.0% 41 
Baseline Absent 0 0.0% 0 0.0% 0 NA NA 
Present 4 19.0% 7 35.0% 11 
4 Weeks Absent 17 81.0% 13 65.0% 30 1.33 0.25
Present 1 4.8% 4 20.0% 5 
8 Weeks Absent 20 95.2% 16 80.0% 36 2.22 0.14
 
 
 
Figure 17:  Comparison of percentage of patients with dysuria. 
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Table 15 shows 
• The number and percentage of patients in probiotic and placebo groups 
with dysuria. 
• The treatment difference was assessed using Chi square test. 
• At baseline, all the patients of probiotic and placebo group had dysuria. 
• There was no significant difference in the frequency of dysuria between 
the probiotic and placebo groups at 4 weeks of study therapy (p=0.25). 
• There was no significant difference in the frequency of dysuria between 
the probiotic and placebo groups at 8 weeks of study therapy (p=0.14). 
 
 
Figure 17- represents a diagrammatic representation of comparison of 
percentage of patients with dysuria in probiotic and placebo groups at baseline, 
and after 4 weeks and 8 weeks of study therapy 
     
 
 
 
 
 
 
 
 
 
 
 Table 16:  Comparison of frequency of occurrence of suprapubic pain. 
 
Group 
Probiotic Placebo 
Variable Number % Number % Total 
Chi 
Square p 
Present 11 52.4% 4 20.0% 15 
Baseline Absent 10 47.6% 16 80.0% 26 4.63 0.03 
Present 0 0.0% 1 5.0% 1 
4 Weeks Absent 21 100.0% 19 95.0% 40 1.1 0.3 
Present 0 0.0% 0 0.0% 0 
8 Weeks Absent 21 100.0% 20 100.0% 41 NA NA 
 
 
Figure 18:  Comparison of percentage of patients with suprapubic pain. 
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Table 16 shows 
• The number and percentage of patients in probiotic and placebo groups 
with suprapubic pain. 
• The treatment difference was assessed using Chi square test. 
• At baseline, there was significant difference in the frequency of suprapubic 
pain between the probiotic and placebo groups (p=0.03). 
• There was no significant difference in the frequency of suprapubic pain 
between the probiotic and placebo groups at 4 weeks of study therapy 
(p=0.3). 
• After 8 weeks of study therapy, there was no report of suprapubic pain by 
any patient in probiotic or placebo group. 
 
 
Figure 18- represents a diagrammatic representation of comparison of 
percentage of patients with suprapubic pain in probiotic and placebo groups at 
baseline, and after 4 weeks and 8 weeks of study therapy 
 
 
 
 
 
 
 
 
 
 Table 17:  Comparison of frequency of occurrence of positive urine culture 
 
Group 
Probiotic Placebo 
VISIT 
Urine 
culture Number % Number % Total 
Chi 
Square p 
Positive 21 100.0% 20 100.0% 41 
Baseline Negative 0 0.0% 0 0.0% 0 NA NA 
Positive 3 14.3% 8 40.0% 11 
4 Weeks Negative 18 85.7% 12 60.0% 30 0.034 0.85 
Positive 1 4.8% 4 20.0% 5 
8 Weeks Negative 20 95.2% 16 80.0% 36 0.05 0.82 
 
Figure 19:Comparison of percentage of patients with positive urine culture. 
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Table 17 shows 
• The number and percentage of patients in probiotic and placebo groups 
with urine culture report. 
• The treatment difference was assessed using Chi square test. 
• At baseline, all the patients of probiotic and placebo group had positive 
urine culture. 
• There was no significant difference in the frequency of positive urine 
culture between the probiotic and placebo groups at 4 weeks of study 
therapy (p=0.85). 
• There was no significant difference in the frequency of positive urine 
culture between the probiotic and placebo groups at 8 weeks of study 
therapy (p=0.82). 
 
 
Figure 19- represents a diagrammatic representation of comparison of 
percentage of patients with positive urine culture in probiotic and placebo groups 
at baseline, and after 4 weeks and 8 weeks of study therapy 
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Table-18 
Variables Group Mean 
Std. 
Deviati
on 
 
 
p 
Probiotic 24.7 2.6 Blood Urea 
Baseline Placebo 24.5 2.9 
0.76 
 
Probiotic 24.6 1.6 Blood Urea  
8 Wks Placebo 23.4 2.4 
 
0.07 
Probiotic 100.5 14.5 Blood Sugar 
 Baseline Placebo 108.7 11.0 
 
0.05 
Probiotic 99.73 9.76 Blood Sugar 
8 Wks Placebo 101.07 9.65 
 
0.71 
Probiotic 0.7 0.1 SrCreatinine 
Baseline Placebo 0.8 0.1 
0.57 
 
Probiotic 0.7 0.1 SrCreatinine 
8 Wks Placebo 0.7 0.1 
 
0.60 
Probiotic 14.9 3.7 SGOT 
Baseline Placebo 15.5 2.2 
0.54 
Probiotic 15.4 2.4 SGOT 
8 Wks Placebo 15.2 1.7 
0.73 
Probiotic 13.3 2.5 SGPT 
Baseline Placebo 12.8 2.6 
0.54 
Probiotic 13.3 2.3 SGPT 
8 Wks Placebo 12.9 2.1 
0.24 
Probiotic 5.9 0.1 TotProt 
Baseline Placebo 5.9 0.2 
0.95 
Probiotic 6.0 0.1 TotProt 
8 Wks Placebo 6.0 0.1 
0.44 
 
 
The above table depicts the difference between probiotic and placebo groups in 
blood urea, blood sugar, serum creatinine, SGOT, SGPT and total proteins taken 
at baseline and end of 8 weeks. By independent samples t test, the difference 
between the treatment groups was not statistically significant (p value > 0.05). 
 
 
 
 
 
 
 
DISCUSSION 
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                     Urogenital infections include those that affect the urethra, urinary 
bladder, vagina and cervix and constitute a worldwide problem that affects more 
than 300 million women/year. Common urogenital infections include bacterial 
vaginosis (BV), vulvovaginal candidiasis (VVC/yeast vaginitis), and urinary tract 
infection (UTI). There is now growing evidence that certain species and strains 
present in the healthy urogenital tract protect the host against infection by 
pathogenic microorganisms.  
                    Probiotics are “Live microorganisms which when administered in 
adequate amounts confer a health benefit on the host.” 6 L. rhamnosus GR-1 and 
L. reuteri RC-14 are extensively characterized urogenital isolates which possess 
a number of properties considered important for urogenital probiotics.39 
Furthermore, studies with humans have shown that these strains are efficacious 
in the prevention and treatment of urogenital infections in women.40, 41  
                                So far, no study of urogenital probiotic strains - Lactobacillus 
rhamnosus GR-1 and Lactobacillus reuteri RC-14 were carried out in our 
population .So we conducted a randomised, double blind, comparative, 
prospective, parallel group study of two-strain combination of oral probiotics - 
Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 as integral 
therapy with conventional treatment in the following female urogenital infections - 
bacterial vaginosis (BV), vulvovaginal candidiasis (VVC or yeast vaginitis) and 
urinary tract infection  (UTI). 
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                         The study was approved by the Ethical committee and was 
conducted in the outpatient clinic of the Department of female Urology and 
Urogynaecology, Government Kasturba Gandhi Hospital for Women and 
Children. 122 patients fulfilled the inclusion criteria and were divided in to three 
groups based on the type of urogenital infection - 
 GROUP I: Patients with bacterial vaginosis (50 patients), 
 GROUP II: Patients with vulvovaginal candidiasis (30 patients), 
 GROUP III:  Patients with urinary tract infection (42 patients). 
Patients of each group were randomly allocated to subgroups A or B to receive 
either of the two study therapies –either integral therapy of probiotics with 
conventional treatment (subgroup A) or placebo with conventional treatment 
(subgroup B). Each 150mg capsule of the probiotic mixture had a minimum of 5 
billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in 
equal proportions and the dosage recommended was two capsules per day for 
eight weeks. The placebo was microcrystalline cellulose. Patients were assessed 
clinically once in two weeks and they were instructed to report to the physician in 
case of any unwanted drug effect. The results were collected and statistically 
analyzed. 
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GROUP-I-BACTERIAL VAGINOSIS 
 Demographic profile 
  Age 
          The mean age of patient in probiotic subgroup was 32.7 years. The mean 
age of patient in placebo subgroup was 31.6 years. The difference in age group 
between the probiotic and placebo subgroups was not statistically significant. Our 
sample reflected the widely published trial conducted in Canada in which the 
mean age of selected patients with bacterial vaginosis was 35 years.66  
 Vaginal pH  
              The difference in mean vaginal pH between the probiotic and placebo 
groups at the baseline (p= 0.36) and at 4 weeks (p= 0. 64) were not statistically 
significant. The difference in mean vaginal pH between the probiotic and placebo 
groups after 8 weeks of study therapy was statistically significant (p= 0. 00) which 
indicate that the probiotic lactobacillus strains confer protection to the host by 
producing an acidic environment. 38 The mean vaginal pH of the probiotic group 
at the end of 4 weeks and 8 weeks were 5.1 and 4.8 which fulfill one of the 
clinical criteria of Amsel et al. for bacterial vaginosis48- vaginal-fluid pH greater 
than 4.5.Many studies have shown that vaginal pH is non-specific and can be 
altered by BV, semen, blood, cervical secretions and lubricating jelly.67 
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 Nugent Score 
                     The difference in mean Nugent score between the probiotic and 
placebo groups at the baseline (p= 0.95) was not statistically significant. The 
difference in mean Nugent score between the probiotic and placebo groups after 
4 weeks (p= 0. 00) and 8 weeks (p= 0. 03) of study therapy was statistically 
significant. Our study results are comparable to a randomised, placebo-controlled 
trial of 64 healthy women which showed restoration from asymptomatic bacterial 
vaginosis microflora to a normal lactobacilli colonized microflora in 37% women 
during lactobacilli treatment compared to 13% on placebo. 57 Another study 
showed a similar result of a significant increase in the degree of purity of the 
vaginal flora.68 
 Vaginal Discharge 
                   At baseline, all the patients of probiotic and placebo group had 
vaginal discharge characteristic of bacterial vaginosis. There was no significant 
difference in the frequency of vaginal discharge characteristic of bacterial 
vaginosis between the probiotic and placebo groups at 4 weeks of study therapy 
(p=0.1). There was a statistically significant difference in the frequency of vaginal 
discharge characteristic of bacterial vaginosis between the probiotic and placebo 
groups at 8 weeks of study therapy (p=0.008). The patients of probiotic group 
reported subjective sense of well-being. 
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 Foul Smelling Odor 
               At baseline, all the patients of probiotic and placebo group had foul 
smelling odor of vaginal discharge. There was no significant difference in the 
frequency of foul smelling odor of vaginal discharge between the probiotic and 
placebo groups at 4 weeks (p=0.26) and 8 weeks (p=0.054) of study therapy. 
 Hematological parameters   
              The total count, differential count, erythrocyte sedimentation rate and 
hemoglobin were within the normal physiological range in both groups. 
 Biochemical Parameters                           
               All the biochemical parameters, blood sugar, blood urea, serum 
creatinine, SGOT, SGPT, serum bilirubin, serum alkaline phosphatase, serum 
proteins and urine routine evaluated during the study period were within the 
normal physiological range. 
 Adverse drug reaction 
                         One patient in probiotic group complained of constipation and 
flatulence. No other significant adverse drug reaction was found in our study. 
No medical intervention was required. Similarly in literature also no side 
effects were reported with the use of probiotics. 
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 GROUP II VULVOVAGINAL CANDIDIASIS  
 Demographic profile 
Age 
                   The mean age of patient in probiotic subgroup was 29.73 years. The 
mean age of patient in placebo subgroup was 30.27 years. The difference 
between the probiotic and placebo was not statistically significant (p= 0.82). 
 Vaginal pH 
                  The difference in mean vaginal pH between the probiotic and placebo 
groups at the baseline (p= 0.72), 4 weeks (p= 0.72) and 8 weeks (p= 0. 07) were 
not statistically significant. Our results are similar to the results of a meta-
analysis, which also showed no difference in mean vaginal pH with study 
therapy.69 
 Composite Sign/ Symptom Score 
                    The difference in mean composite sign/ symptom score between the 
probiotic and placebo groups at the baseline (p= 0.39), 4weeks(p= 0.72) and 8 
weeks (p= 0.72) were not statistically significant. 
 Microscopic analysis with potassium hydroxide preparation 
                     At baseline, all the patients of probiotic and placebo group had KOH 
preparation of vaginal smear positive for candida. There was no significant 
difference in the frequency of KOH preparation of vaginal smear positive for 
candida between the probiotic and placebo groups at 4 weeks (p=0.54) and 8 
weeks (p=0.54) of study therapy.  
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                       A randomised, placebo-controlled trial recorded significant 
reduction in number of positive cultures for candida consistent with the use of L 
rhamnosus GR-1 and L fermentum RC-14 in lyophilized capsule form, which 
showed up to one log fewer yeast recovered from the vagina during treatment 
compared with baseline.57In our study, candida culture was not done. Further 
studies are needed to assess the efficacy of probiotic strains in VVC. 
 Hematological parameters   
                         The total count, differential count, erythrocyte sedimentation rate 
and hemoglobin were within the normal physiological range in both groups. 
 Biochemical Parameters                           
                          All the biochemical parameters, blood sugar, blood urea, serum 
creatinine, SGOT, SGPT, serum bilirubin, serum alkaline phosphatase, serum 
proteins and urine routine evaluated during the study period were within the 
normal physiological range. 
 Adverse drug reaction 
                         No significant adverse drug reaction was found in our study. 
No medical intervention was required. Similarly in literature also no side 
effects were reported with the use of probiotics. 
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GROUP-III URINARY TRACT INFECTION 
 
• Demographic profile 
Age 
                      The mean age of patient in probiotic subgroup was 35years. The 
mean age of patient in placebo subgroup was 36.1years.The difference between 
the mean age of probiotic and placebo subgroups was not statistically significant 
(p= 0.57).Our sample reflected the widely published trial in which the mean age 
of selected patients with bacterial vaginosis was 30.3 years. 70 
• There was no significant difference in the frequency of dysuria, fever and 
suprapubic pain between the probiotic and placebo groups. 
• Urine culture 
                     At baseline, all the patients of probiotic and placebo group had 
positive urine culture. There was no significant difference in the frequency of 
positive urine culture between the probiotic and placebo groups at 4 weeks 
(p=0.85) and 8 weeks (p=0.82) of study therapy. Results from various studies 
indicate that the recurrence rate of UTI was significantly reduced after using one 
or two capsules vaginally per week for one year, with no side effects or yeast 
infections.64In our study, the patients were followed up only for a period of 8 
weeks. Further studies are needed to assess the efficacy of probiotic strains in 
reducing recurrence rate of UTI per year. 
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• Hematological parameters   
The total count, differential count, Erythrocyte Sedimentation Rate and 
Hemoglobin were within the normal physiological range in both groups. 
• Biochemical Parameters                           
All the biochemical parameters, blood sugar, blood urea, serum creatinine, 
SGOT, SGPT, serum bilirubin, serum alkaline phosphatase, serum proteins and 
urine routine evaluated during the study period were within the normal 
physiological range. 
• Adverse drug reaction 
                      No significant adverse drug reaction was found in our study. No 
medical intervention was required. Similarly in literature also no side effects were 
reported with the use of these probiotic lactobacilli strains. 
 
                     In a climate of the trend toward reduced antibiotic use, awareness 
of disease resulting directly from micro ecosystem disruption, emergence of 
pathogens with enhanced virulence, clinical conditions refractory to conventional 
treatment, and awareness that some infections lead to serious sequelae, 
probiotic bacteria may add a low-cost, low risk layer of protection from infection 
and disease. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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The eight week, randomised, double blind, comparative, prospective, parallel 
group study of two-strain combination of oral probiotics - Lactobacillus 
rhamnosus GR-1 and Lactobacillus reuteri RC-14 as integral therapy with 
conventional treatment in female urogenital infections showed – 
 
 Significant therapeutic effect in the management of Bacterial 
vaginosis (BV), 
 
 The combination therapy was not significant in the management of 
Vulvovaginal candidiasis (VVC or yeast vaginitis) and Urinary tract 
infection (UTI). 
 
 
 Oral urogenital probiotic strains - Lactobacillus rhamnosus GR-1 and 
Lactobacillus reuteri RC-14 were found to be safe and well tolerated. 
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                                                                            Appendix 1 
 
 
ABBREVIATIONS 
 
 
 
BV 
 
Bacterial Vaginosis 
 
CFUs 
 
Colony Forming Units 
 
CFUs/gm 
 
Colony Forming Units per gram 
 
CI 
 
Confidence Interval 
 
FAO 
 
Food and Agriculture Organization 
 
HIV 
 
Human Immunodeficiency Virus 
 
H2O2 
 
Hydrogen peroxide 
 
KOH 
 
Potassium Hydroxide 
 
L. 
 
Lactobacillus 
 
SGOT 
 
Serum Glutamic Oxaloacetic Transaminase 
 
SGPT 
 
Serum Glutamic Pyruvic Transaminase 
 
Std.Deviation 
 
Standard Deviation 
 
Tot.Prot. 
 
Total Protein 
 
UTI 
 
Urinary Tract Infection 
 
VVC 
 
VulvoVaginal Candidiasis 
 
WHO 
 
World Health Organization 
 
 
 
 
 
 
 
 
Appendix 2 
Informed Consent Form-English 
 
Study Title: 
“A Randomised, Double Blind, Comparative, Prospective, Parallel Group Study Of Oral Probiotics 
In Female Patients With Urogenital Infections” 
Name:  ________________________ O.P.No.       :    ________________ 
Address : ________________________   Enroll No.:    ________________  
  ________________________            Age       :    ________________ 
                             ________________________            Sex    :     Female 
                             ________________________ 
I, ________________________________________________ Age _____________ Yrs, exercising my free 
power of choice, hereby give my consent to be included as a patient in the clinical study “A Randomised, 
Double Blind, Comparative, Prospective, Parallel Group Study of Oral Probiotics In Female Patients with 
Urogenital Infections” 
I agree to the following: 
• I have been informed to my satisfaction about the purpose of the study, nature of the drug 
treatment, follow up visits and study procedures including investigations, to monitor and to 
safeguard my body function. 
• I understand that the laboratory investigations will require the withdrawal of blood sample in 
required amount at follow up visits. 
• I agree to co-operate fully and to inform the doctor immediately if I suffer any unusual symptom. 
• I have informed the doctor, about all medications that I have taken in the recent past and those I 
am currently taking. I shall not take any medications without the agreement of the supervising 
doctor. 
• I understand that study doctor may stop my participation in the study for any reasons. I am also 
aware of my right to opt out of the study at any time during the study duration without giving any 
reason. 
• I hereby give permission to use my medical records for research purpose. I am told that study 
doctor and study institution will keep my identity close. 
 
      ______________________          ______________________          ______________________ 
      Name of the Patient                  Signature/Thumb impression                  Date 
      ______________________          ______________________          ______________________ 
       Name of Impartial Witness       Signature        Date 
      ______________________          ______________________          ______________________ 
       Name of the Investigator                     Signature         Date  
 
Consent form - Tamil 
 
Bµõ´a] J¨¦uÀ £iÁ® 
  
 
ö£¯ º   :  ____________________ ¦Ó ÷{õ¯ õÎ Gs. :  ____________________ 
 
¬PÁ¶:  _____________________ Bµõ´a] ÷\ºUøP Gs :  ____________________ 
 
 _____________________ Á¯ x   :  ____________________ 
 
 _____________________ £õ¼Ú®  :   ö£s 
 
 {õß ...................................................... Á¯ x ..................................... GßÝøh¯  
_¯ |øÚÄhß ©ØÖ® ¬Ê _u¢vµzxhß, C¢u ©¸zxÁ Bµõ´a]°À GßøÚ  ÷\ºzxU öPõÒÍ 
\®©vUQ÷Óß. 
 
 Bµõ´a]°ß uø»¨¦ ""G ÷µshø©ìk, h¤Ò ¤øÍsm, P®£÷µmiÆ, ¨µõìö£UiÆ, ÷£µ»À S¹¨ 
ìhi BL¨ ¦÷µõ£¯ õiUì Cß L¥÷©À ÷£åßmì Âz ±÷µõöáÛhÀ Cßö£Uåß''  GßÖ® AÔQ÷Óß. 
 
GÚUS ÂÍUP¨£mh RÌUPsh Âå¯ [PÐUS {õß GÚx \®©uzøu u¸Q÷Óß. 
 
• C¢u Bµõ´a]°ß ÷{õUP® ©¸zxÁ ¬øÓPÒ, £¶÷\õuøÚ ¬øÓPÒ, GÚ US v¸¨v²Ö® ÁøP°À 
ÂÍUP¨£mhÚ. 
 
• £¶÷\õuøÚ ö\´ÁuØPõP  Gß Eh¼¼¸¢x Cµzu® ©ØÖ® ]Ö}º GkUP¨£h ÷Ási²ÒÍuõP 
AÔQ÷Óß. 
 
• {õß Gkzx Á¸QßÓ ©ØÖ® ¬ß¦ EmöPõsh ©¸¢xPÒ £ØÔ¯  ÂÁµ[PøÍ Bµõ´a]¯ õÍ¶h® 
AÔÂUP \®©u®. C¢u £[öPzu¼ß ¤ß¦ AÁ¶ß AÝ©v°ßÔ {õß G¢u ©¸¢x® 
EmöPõÒÍ©õm÷hß GßÖ® öu¶ÂUQ÷Óß. 
 
• GÚUS® ©ØÖ® ©¸¢x Bµõ´a]¯ õÍ¸US® C¢u Bµõ´a]°¼¸¢x G¢u J ¸ |ø»°¾® 
Â»SÁuØ÷Põ AÀ»x Â»USÁuØ÷Põ ¬Ê E¶ø© C¸¨£uõP AÔQ÷Óß. 
 
• GßÝøh¯  ©¸zxÁU SÔ¨÷£kPøÍ C¢u Bµõ´a]°À £¯ ß£kzvU öPõÒÍ  \®©vUQ÷Óß. 
Bµõ´a] ø©¯ ¬®, Bµõ´a]¯ õÍ¸® GßÝøh¯  ö£¯ º ©ØÖ® ]À ÂÁµ[PøÍ CµP]¯ ©õP øÁ¨£uõP 
AÔQ÷Óß. 
 
 
__________________  __________________  __________________ 
÷{õ¯ õÎ°ß ö£¯ º           øPö¯ Êzx   ÷uv 
 
 
__________________  __________________  __________________ 
   \õm]°ß ö£¯ º          øPö¯ Êzx   ÷uv 
 
 
 
__________________  __________________  __________________ 
 Bµõ´]¯ õÍ¶ß ö£¯ º          øPö¯ Êzx   ÷uv 
 
 
 
Appendix 3 
PROFORMA 
 
“A Randomised, Double Blind, Comparative, Prospective, Parallel Group Study Of Oral 
Probiotics In Female Patients With Urogenital Infections” 
 
1. Name:                                                                                            Date 
2. Age: 
3. Address: 
4. OP No.  :  
5. Randomization No: ____________       
  Body Measurement 
Height:  ___________ mts                           Weight:  ____________ Kg 
 
BMI:  __________ Kg/m2 
 
Demography 
Age: 
Sex:   Female    
Vital Signs  
Blood Pressure:  ___________ / ___________ mmHg 
Pulse:  _______________ Beats Per minute 
 
Medical History 
 
Concomitant Illness:  
 
Concomitant Medications:                                                                                     
 
UROGENITAL EXAMINATION: 
INVESTIGATIONS:    Following basal investigation were done for all the patients                                                                                   
Complete blood count  
Hb g% TC  DC          ESR 
 
 
 
   
Routine  Urine Analysis :   
       Albumin g/dL Sugar g/dL WBC/ RBC Casts 
 
 
 
 
   
Midstream Urine  Colony count &Culture-Sensitivity:   
Vaginal /Cervical  --- swab/smear. examination  
 
1.Vaginal smear for Gram staining [Nugent’s Diagnostic Method] 
 
 Nugent Scores of Gram Stain :    ________________    
 
2) Vaginal smear for 10% KOH mount: - Budding Yeast  Yes  No 
 
 Vaginal pH monitoring:  
 
Ultrasound  Abdomen  ---  
 
Blood Chemistry – 
Blood Sugar:  ------------------ mg/dL 
 
Liver Function Tests and Renal Function Tests: 
 
SGOT U/L SGPT U/L Bilirubin mg/dL 
 
Alkaline 
Phosphatase 
U/L 
Urea 
mg/dL 
Creatinine 
mg/dL 
 
 
 
     
 
Clinical Response Evaluation: 
 
INVESTIGATIONS DONE AT THE END OF 4 WEEKS 
Bacterial Vaginosis: 
1.Vaginal smear for Gram staining [Nugent’s Diagnostic Method] 
 
                    Nugent Scores of Gram Stain :    ________________    
2) pH of Vaginal Fluid    _________________   
 
Vulvovaginal Candidiasis: 
1) Vaginal smear for 10% KOH mount: - Budding Yeast  Yes  No 
 2) pH of Vaginal Fluid    _________________   
 
Urinary Tract Infection: 
1) Routine Urine analysis: 
 
       Albumin g/dL Sugar g/dL WBC/ RBC Casts 
 
 
 
 
   
 
2) Midstream Urine Colony count &Culture-Sensitivity 
 
Clinical Response Evaluation: 
INVESTIGATIONS DONE AT THE END OF 8 WEEKS 
Bacterial Vaginosis: 
1.Vaginal smear for Gram staining [Nugent’s Diagnostic Method] 
 
                    Nugent Scores of Gram Stain :    ________________    
2) pH of Vaginal Fluid    _________________   
 
Vulvovaginal Candidiasis: 
1) Vaginal smear for 10% KOH mount: - Budding Yeast  Yes  No 
 2) pH of Vaginal Fluid    _________________   
 
Urinary Tract Infection: 
1) Routine Urine analysis: 
 
       Albumin g/dL Sugar g/dL WBC/ RBC Casts 
    
 
2) Midstream Urine Colony count &Culture-Sensitivity 
 
Other Investigations: 
 
Blood Routine: 
 
Hb g% TC  DC          ESR 
 
 
 
   
 
Blood Sugar :  ------------------ mg/dL 
 
Liver Function Tests and Renal Function Tests: 
 
SGOT U/L SGPT U/L Bilirubin mg/dL 
 
Alkaline 
Phosphatase 
U/L 
Urea 
mg/dL 
Creatinine 
mg/dL 
 
 
 
     
 
 
Clinical Response Evaluation: 
   
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
